Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex Pharmaceuticals Holding AB (publ)Tomtebodavägen 23aSE-171 77 Stockholm, Sweden
NLS Insight's goal is to assist the Nordic regions leading innovators in targeting business collaborations, parnership opportunities and investment potential.
Designed by Horn Digital Media 2017